Skip to main content

Table 2 Different MIC breakpoints for azithromycin used in the European gonococcal External Quality Assessments (EQAs) from 2007 to 2012

From: Ten years of external quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in Europe elucidate high reliability of data

No. of laboratories* (n = 104) No. of laboratories 2007 (n = 12) No. of laboratories 2012 (n = 14) Azithromycin MIC breakpoints (mg/L)
S ≤ I R >
31 (29.8%) 4 (33.3%) 4 (28.6%) 0.5 0.5
29 (27.9%) 0 6 (42.9%) 0.25a 0.5a 0.5a
11 (10.6%) 2 (16.7%) 1 (7.1%) 1 1b
7 (6.7%) 2 (16.7%) 0 0.5 1 1
6 (5.8%) 1 (8.3%) 0 2
6 (5.8%) 0 2 (14.3%) 0.25 0.25
1 (1.0%) 0 0 0.125 0.25–0.5 0.5
1 (1.0%) 0 0 0.125 0.25–1 1
1 (1.0%) 1 (8.3%) 0 0.25 0.5–1 1
1 (1.0%) 1 (8.3%) 0 4   
10 (9.6%) 1 (8.3%) 1 (7.1%) None given
  1. Note: Detailed interpretative MIC data was only available until 2012. Adherence to published breakpoints collected post-2012
  2. *Includes total number of participants at each distribution, i.e. the same laboratory will be counted at each distribution
  3. aCurrent EUCAST breakpoints
  4. bUS GISP alert value MIC (https://www.cdc.gov/std/gisp/GISP-Protocol-May-2016.pdf)